Volta Medical Welcomes Bill Hoffman as New Executive Chairman of the Board

Bill Hoffman Appointed as Executive Chairman at Volta Medical

Volta Medical, a pioneering health technology firm specializing in artificial intelligence (AI) solutions for electrophysiologists, has announced the appointment of Bill Hoffman as the Executive Chairman of its Board of Directors. This strategic leadership change comes as the company seeks to enhance its innovative offerings in the cardiac care sector.

Bill Hoffman brings a wealth of experience in guiding startups to global success. He previously served as the Chief Executive Officer of Inari Medical, where he was instrumental in scaling the company from its inception to a publicly traded entity, achieving over $500 million in revenue. Under his leadership, Inari Medical made significant strides in the treatment of venous thromboembolism, culminating in its acquisition by Stryker for a staggering $4.9 billion in February 2025.

CEO and Co-founder of Volta Medical, Théophile Mohr-Durdez, expressed enthusiasm about Hoffman's appointment, stating, "We are privileged to welcome Bill Hoffman as Executive Chairman. His extensive experience in building, marketing, and scaling groundbreaking medical technologies will be invaluable as we expedite global access to our AI-driven cardiac ablation solutions."

Hoffman himself is excited about the new role. He remarked, "The technology developed by Volta has demonstrated clinically significant improvements in patient outcomes for those with atrial fibrillation (AF). It's thrilling to join the Volta team and collaborate on our mission to provide exceptional support to our patients."

In conjunction with Hoffman's appointment, Volta also named Dr. Jerome Kalifa as the Executive Vice Chairman. Dr. Kalifa will continue to serve as the Chief Medical Officer, reinforcing the leadership team that is dedicated to eliminating AF in as many patients as possible, and as quickly as possible.

This leadership transition follows the recent publication of the groundbreaking TAILORED-AF study in Nature Medicine. The study exhibited that an AI-assisted procedure utilizing Volta's technology combined with traditional pulmonary vein isolation (PVI) yielded significantly better outcomes for patients with persistent atrial fibrillation compared to PVI alone.

Understanding Atrial Fibrillation

According to the American Heart Association (AHA), atrial fibrillation (AF) is characterized by an irregular heartbeat that can lead to blood clots, strokes, heart failure, and other heart-related complications. Approximately 33 million individuals worldwide suffer from AF. Despite its serious nature—where untreated AF doubles the risk of death and increases the chances of stroke by five times—many patients remain unaware of the condition's severity. Currently, only about 15% of the 2.5 million eligible patients in the U.S. are treated with catheter ablation, signifying a significant treatment gap.

Volta Medical aims to bridge this gap by developing AI software solutions designed to assist cardiologists in managing heart rhythm disorders, thereby improving clinical outcomes for their patients. Founded in 2016 in Marseille, France, by three physicians and a data scientist, Volta Medical's mission is to enhance the treatment of arrhythmias by developing state-of-the-art, data-driven medical devices based on extensive procedural databases. The Volta AF-Xplorer™ is a digital AI assistant that helps cardiologists identify specific abnormal electrograms (EGMs) in real-time, which are critical for diagnosing AF and atrial tachycardia. The AF-Xplorer is compatible with major AF mapping and recording systems, as well as various ablation modalities. The solution has received FDA 510(k) clearance in the United States and is CE marked in Europe. Furthermore, Volta Medical has established an outreach program to educate underserved AF patients about their treatment options.

For more detailed information, visit Volta Medical's website.